Literature DB >> 25378161

Parvalbumin and GAD65 interneuron inhibition in the ventral hippocampus induces distinct behavioral deficits relevant to schizophrenia.

Robin Nguyen1, Mark D Morrissey1, Vivek Mahadevan2, Janine D Cajanding2, Melanie A Woodin2, John S Yeomans3, Kaori Takehara-Nishiuchi3, Jun Chul Kim4.   

Abstract

Hyperactivity within the ventral hippocampus (vHPC) has been linked to both psychosis in humans and behavioral deficits in animal models of schizophrenia. A local decrease in GABA-mediated inhibition, particularly involving parvalbumin (PV)-expressing GABA neurons, has been proposed as a key mechanism underlying this hyperactive state. However, direct evidence is lacking for a causal role of vHPC GABA neurons in behaviors associated with schizophrenia. Here, we probed the behavioral function of two different but overlapping populations of vHPC GABA neurons that express either PV or GAD65 by selectively inhibiting these neurons with the pharmacogenetic neuromodulator hM4D. We show that acute inhibition of vHPC GABA neurons in adult mice results in behavioral changes relevant to schizophrenia. Inhibiting either PV or GAD65 neurons produced distinct behavioral deficits. Inhibition of PV neurons, affecting ∼80% of the PV neuron population, robustly impaired prepulse inhibition of the acoustic startle reflex (PPI), startle reactivity, and spontaneous alternation, but did not affect locomotor activity. In contrast, inhibiting a heterogeneous population of GAD65 neurons, affecting ∼40% of PV neurons and 65% of cholecystokinin neurons, increased spontaneous and amphetamine-induced locomotor activity and reduced spontaneous alternation, but did not alter PPI. Inhibition of PV or GAD65 neurons also produced distinct changes in network oscillatory activity in the vHPC in vivo. Together, these findings establish a causal role for vHPC GABA neurons in controlling behaviors relevant to schizophrenia and suggest a functional dissociation between the GABAergic mechanisms involved in hippocampal modulation of sensorimotor processes.
Copyright © 2014 the authors 0270-6474/14/3414948-13$15.00/0.

Entities:  

Keywords:  DREADD; GABA; parvalbumin; schizophrenia; ventral hippocampus

Mesh:

Substances:

Year:  2014        PMID: 25378161      PMCID: PMC4220027          DOI: 10.1523/JNEUROSCI.2204-14.2014

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  85 in total

1.  Afferent modulation of dopamine neuron firing differentially regulates tonic and phasic dopamine transmission.

Authors:  Stan B Floresco; Anthony R West; Brian Ash; Holly Moore; Anthony A Grace
Journal:  Nat Neurosci       Date:  2003-09       Impact factor: 24.884

2.  The medial septum mediates impairment of prepulse inhibition of acoustic startle induced by a hippocampal seizure or phencyclidine.

Authors:  Jingyi Ma; Bixia Shen; N Rajakumar; L Stan Leung
Journal:  Behav Brain Res       Date:  2004-11-05       Impact factor: 3.332

Review 3.  The value of spontaneous alternation behavior (SAB) as a test of retention in pharmacological investigations of memory.

Authors:  Robert N Hughes
Journal:  Neurosci Biobehav Rev       Date:  2004-09       Impact factor: 8.989

4.  Response perseveration of rats with dorsal hippocampal lesions.

Authors:  T Dalland
Journal:  Behav Biol       Date:  1976-08

5.  Effects of dorsal and ventral hippocampal lesions on spontaneous alternation, learned alternation and probability learning in rats.

Authors:  R Stevens; A Cowey
Journal:  Brain Res       Date:  1973-03-30       Impact factor: 3.252

Review 6.  The radial arm maze as a tool in behavioral pharmacology.

Authors:  D S Olton
Journal:  Physiol Behav       Date:  1987

7.  Hippocampal signal transmission to the pedunculopontine nucleus and its regulation by dopamine D2 receptors in the nucleus accumbens: an electrophysiological and behavioural study.

Authors:  C R Yang; G J Mogenson
Journal:  Neuroscience       Date:  1987-12       Impact factor: 3.590

8.  Disruption of neurogenesis on gestational day 17 in the rat causes behavioral changes relevant to positive and negative schizophrenia symptoms and alters amphetamine-induced dopamine release in nucleus accumbens.

Authors:  Peter Flagstad; Arne Mørk; Birte Y Glenthøj; Johan van Beek; Adina T Michael-Titus; Michael Didriksen
Journal:  Neuropsychopharmacology       Date:  2004-11       Impact factor: 7.853

Review 9.  Hippocampal modulation of sensorimotor processes.

Authors:  Tobias Bast; Joram Feldon
Journal:  Prog Neurobiol       Date:  2003-07       Impact factor: 11.685

10.  Sociability and preference for social novelty in five inbred strains: an approach to assess autistic-like behavior in mice.

Authors:  S S Moy; J J Nadler; A Perez; R P Barbaro; J M Johns; T R Magnuson; J Piven; J N Crawley
Journal:  Genes Brain Behav       Date:  2004-10       Impact factor: 3.449

View more
  37 in total

Review 1.  Seeing through the smoke: Human and animal studies of cannabis use and endocannabinoid signalling in corticolimbic networks.

Authors:  Mason M Silveira; Jonathon C Arnold; Steven R Laviolette; Cecilia J Hillard; Marta Celorrio; María S Aymerich; Wendy K Adams
Journal:  Neurosci Biobehav Rev       Date:  2016-09-14       Impact factor: 8.989

2.  Gi-DREADD Expression in Peripheral Nerves Produces Ligand-Dependent Analgesia, as well as Ligand-Independent Functional Changes in Sensory Neurons.

Authors:  Jami L Saloman; Nicole N Scheff; Lindsey M Snyder; Sarah E Ross; Brian M Davis; Michael S Gold
Journal:  J Neurosci       Date:  2016-10-19       Impact factor: 6.167

3.  Cytosolic Accumulation of L-Proline Disrupts GABA-Ergic Transmission through GAD Blockade.

Authors:  Gregg W Crabtree; Alan J Park; Joshua A Gordon; Joseph A Gogos
Journal:  Cell Rep       Date:  2016-10-04       Impact factor: 9.423

4.  Local Perturbations of Cortical Excitability Propagate Differentially Through Large-Scale Functional Networks.

Authors:  Zachary P Rosenthal; Ryan V Raut; Ping Yan; Deima Koko; Andrew W Kraft; Leah Czerniewski; Benjamin Acland; Anish Mitra; Lawrence H Snyder; Adam Q Bauer; Abraham Z Snyder; Joseph P Culver; Marcus E Raichle; Jin-Moo Lee
Journal:  Cereb Cortex       Date:  2020-05-14       Impact factor: 5.357

Review 5.  Cognitive deficits caused by prefrontal cortical and hippocampal neural disinhibition.

Authors:  Tobias Bast; Marie Pezze; Stephanie McGarrity
Journal:  Br J Pharmacol       Date:  2017-06-07       Impact factor: 8.739

6.  Environmental Enrichment Prevent the Juvenile Hypoxia-Induced Developmental Loss of Parvalbumin-Immunoreactive Cells in the Prefrontal Cortex and Neurobehavioral Alterations Through Inhibition of NADPH Oxidase-2-Derived Oxidative Stress.

Authors:  Mingqiang Zhang; Jing Wu; Lan Huo; Liang Luo; Xi Song; Fei Fan; Yiming Lu; Dong Liang
Journal:  Mol Neurobiol       Date:  2015-12-23       Impact factor: 5.590

Review 7.  Sensorimotor gating of the startle reflex: what we said 25 years ago, what has happened since then, and what comes next.

Authors:  Neal R Swerdlow; David L Braff; Mark A Geyer
Journal:  J Psychopharmacol       Date:  2016-08-18       Impact factor: 4.153

8.  Bidirectional Control of Anxiety-Related Behaviors in Mice: Role of Inputs Arising from the Ventral Hippocampus to the Lateral Septum and Medial Prefrontal Cortex.

Authors:  Gustavo Morrone Parfitt; Robin Nguyen; Jee Yoon Bang; Afif J Aqrabawi; Matthew M Tran; D Kanghoon Seo; Blake A Richards; Jun Chul Kim
Journal:  Neuropsychopharmacology       Date:  2017-03-15       Impact factor: 7.853

9.  Schizophrenia-like reduced sensorimotor gating in intact inbred and outbred rats is associated with decreased medial prefrontal cortex activity and volume.

Authors:  Carles Tapias-Espinosa; Cristóbal Río-Álamos; Ana Sánchez-González; Ignasi Oliveras; Daniel Sampedro-Viana; Maria Del Mar Castillo-Ruiz; Toni Cañete; Adolf Tobeña; Alberto Fernández-Teruel
Journal:  Neuropsychopharmacology       Date:  2019-04-16       Impact factor: 7.853

Review 10.  Cell-based therapies for the treatment of schizophrenia.

Authors:  Jennifer J Donegan; Daniel J Lodge
Journal:  Brain Res       Date:  2016-08-18       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.